Patients need to know that treatments are recommended based on patient need, not pharma company interests. That’s why it’s important to know how much Big Pharma is paying to health-care providers and organizations.
(Shutterstock)
Canada has a lack of transparency about Big Pharma’s payments to health-care providers and organizations. Disclosure is voluntary, and there’s no central data on even the few companies that do report.
Over 90 per cent of Canadian doctors see pharmaceutical sales representatives.
(Shutterstock)
Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.
The analgesic Grand-pa is among the most common pharmatrash in this study.
Rebecca Hodes
From colonial poppy fields to pharmatrash, southern Africa offers a fascinating history of drug regimes – one that helps us make sense of drug policies and legislation today.
Protests and lawsuits against opioid manufacturers are growing more common, but drug distributors are also facing scrutiny.
AP Photo/Charles Krupa
Previously secret documents and data make it clear that many companies engaged in the distribution of prescription painkillers either skirted or ignored their legal obligations for years.
Australia is within reach of achieving its pledge to end new HIV transmissions by 2020.
Shutterstok
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
In this March 18, 2011 photo, Cassidy Hempel waved at hospital staff as she was being treated for a rare disorder. Her mother Chris, left, fought to gain permission for an experimental drug.
AP Photo/Marcio Jose Sanchez
Holding patents can be a lucrative and powerful position to be in. Here’s a proposal for how nonprofit patent holders can do more for the common good – and live up to their end of the tax break bargain.
Thalidomide’s manufacturer, Chemie Grünenthal, marketed the drug as safe for pregnant women despite reports it was causing malformations in newborns. Why such blatant denial?
Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University